13/09/2024 Intravenous infliximab biosimilars for treating inflammatory conditions
The Ministry of Health’s Drug Advisory Committee has recommended to:
- Reclassify infliximab biosimilar (Remsima) 100 mg vial from the Medication Assistance Fund (MAF) to the MOH Standard Drug List (SDL); and
- List infliximab biosimilar (Ixifi) 100 mg vial on the SDL
in view of favourable cost effectiveness compared to other anti-tumour necrosis factor alfa (anti-TNFα) biologics at the prices proposed by the manufacturers.
Subsidy status
RSDL subsidy will apply for all registered indications of infliximab biosimilar 100 mg vial (Remsima and Ixifi) in Singapore:
- Adults with moderately to severely active rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, ulcerative colitis or Crohn’s disease;
- Children aged 6 years or older with severe active Crohn’s disease; and
- Children aged 6 years or older with moderately to severely active ulcerative colitis.
NRSDL subsidy does not apply to proprietary infliximab 100 mg vial (Remicade) or other brands of infliximab biosimilars.